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Sir,
We thank Dr Chun-Ru Chien et al for their interest in our recent
study and for their remarks concerning the safety of using involved-
field irradiation in treating limited-stage small-cell lung cancer
(SCLC). We have updated our analysis of failure patterns in patients
with limited-stage SCLC who were treated in our phase II study of
involved-field irradiation during the second and third cycles of
carboplatin, paclitaxel and etoposide (Baas et al, 2006). Of the 36
patients, isolated out-of-field nodal failures were only seen in two
patients, one of whom developed an ipsilateral supraclavicular nodal
recurrence after 10 months and the other developed a recurrence in
the left hilar region after 18 months follow-up. In-field recurrences
were observed in nine patients, and this was the sole site of recurrence
in four patients. One patient developed a large-cell carcinoma within
the treatment field 5.2 years after the diagnosis of SCLC. In two other
patients, simultaneous recurrences manifested both within- and
out-of-field regional nodes. A further two patients presented with a
simultaneous local recurrence and distant metastases.
Recently, De Ruysscher et al (2006)published their prospective
evaluation of patterns of recurrence in twenty-seven limited-stage
SCLC patients irradiated without elective nodal fields (without
use of 18-fluoro-2-deoxyglucose positron-emission tomography
(18FDG-PET) scans). Three of their 27 patients developed an
isolated nodal failure in the ipsilateral supraclavicular region. They
concluded that the omission of elective nodal irradiation in SCLC
patients should be performed in the context of trials only. It could
be argued that the dose used in our trial of 45Gy in 5 weeks was
too low, and local recurrences occurred before nodal failures
became evident. De Ruysscher prescribed a more intense radio-
therapy schedule of 45Gy given in 3 weeks (twice daily irradiation
with a 6–8h interval). It is unclear as to why the supraclavicular
region was prone to isolated recurrences. In general, this area is
difficult to assess on the computed tomography (CT) scan of the
thorax (and is often not fully accessed). A solution for this problem
is to ensure an optimal contrast-enhanced CT scan, which includes
the supraclavicular region. The addition of a routine ultrasound
of the supraclavicular area has been shown to improve staging
in both NSCLC (non-small-cell lungs cancer) and SCLC (Van
Overhagen et al, 2004). In addition, recent literature suggests that
18FDG-PET scans could be of additional value in staging patients
with limited-stage SCLC (Bradley et al, 2004; Fischer et al, 2007).
A phase III trial of concurrent chemoradiotherapy without
elective nodal irradiation in limited-stage SCLC, where patients
will be randomised to either once daily irradiation to a dose of
66Gy or twice daily irradiation to a dose of 45Gy will shortly
commence (Faivre-Finn, 2006). Such a trial will generate more
reliable data on the safety of omitting elective nodal irradiation in
this disease. Until additional data become available, we would
suggest that optimal nodal staging that incorporates an ultrasound
examination of the neck, and possibly use of 18FDG-PET scan
should be performed for patients undergoing involved-field
radiotherapy for limited-stage SCLC.
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